No results for ‘’
Novartis India Ltd
NSE: NOVARTIND BSE: 500672
₹2046.80
(1.70%)
Thu, 24 Sept 2026, 08:00 pm
Market Cap (in Cr)5137.78
PE Ratio51.69
Dividend1.20
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1928
- Ciba Dyes Pvt Ltd registered on 13 June in India dealing in dyestuffs and pharmaceuticals.
1947
- Registered on 13 December as Ciba Pharma Pvt Ltd, wholly owned subsidiary of Ciba Ltd Basle, to take over pharma trading from Ciba (India) Ltd.
1948
- Ciba (India) Ltd name changed to Ciba Dyes Pvt Ltd effective 1 March.
1960
- Amalgamation of Ciba Dyes Pvt Ltd with the Company effective 31 December.
1961
- Company incorporated on 5 January.
- Name changed from Ciba Pharma Pvt Ltd to Ciba of India Ltd after amalgamation.
1965
- Issues 25,000 rights equity shares at par in 1:2 proportion on 9 July.
1966
- Issues 250,000 bonus equity shares in 10:3 proportion on 17 October.
1970
- Name changed to Ciba-Geigy of India Ltd effective 21 October.
1971
- Manufactures pesticides at Santa Monica, Goa plant for cotton, rice, oilseeds, pulses, vegetables, fruits.
- Issues 162,500 bonus shares in 1:2 proportion on 18 October.
- Ciba-Geigy Basle holds 316,875 shares out of total issued till December.
- Manufactures consumer products including toothbrushes under BINACA at Bhandup.
- Licensed User Agreement for trademarks dated 14 October (modified 14 August 1974) with Ciba-Geigy Basle.
1975
- Issues 130,000 bonus shares in 4:15 proportion on 16 June.
- Licensed User Agreement for trademarks dated 5 February with Ciba-Geigy Basle.
1977
- Issues 308,750 bonus shares in 1:2 proportion on 14 November.
- Licensed User Agreement for trademarks dated 29 March 1978 with Ciba-Geigy Basle.
1980
- Issues 463,125 bonus shares in 1:2 proportion on 9 October.
1982
- Agreement dated 11 March with Ciba-Geigy Basle.
- Licensed User Agreement for trademarks dated 12 August with Ciba-Geigy Basle.
- Issues 463,125 bonus shares in 1:2 proportion.
1983
- Name changed to Hindustan Ciba-Geigy Ltd effective 1 January.
- RBI permits Ciba-Geigy Switzerland to disinvest 194,783 shares at Rs 75 premium to resident Indians.
- Public issue of 381,400 shares at Rs 40 premium to dilute foreign equity from 65% to 51%.
- Licensed User Agreement for trademarks dated 17 March with Ciba-Geigy Basle.
1985
- Permitted to use CIBACA trademark; BINACA allowed transitionally until end of 1986.
- Markets Araldite epoxy resins for industrial applications including aerospace.
1988
- Launches Voveran SR sustained release formulation.
- Introduces Ridomil M272 WP for grapes and tobacco diseases, Fasinex for flukes in cattle and sheep.
- Receives LOI for 700 tpa saturated polyester resins for powder coatings.
1989
- Receives LOI for 1200 tpa speciality chemicals for detergents, dyes, textiles.
- Agreement with UCB SA Belgium to manufacture saturated polyester resins.
- Receives LOI for anti-oxidants with Ciba-Geigy technical know-how.
- Modernises agricultural chemicals division plant facilities.
1990
- Dyes and chemicals division consolidates position in leather chemicals.
- LOI for saturated polyester resins converted to industrial licence; plans new plant with UCB SA Belgium.
- Offers private placement of 10-14 lakh 14% NCD of Rs 100, redeemable at 5% premium in three instalments after 6-8 years.
- Issues 885,387 bonus shares in 1:2 proportion.
1991
- Test markets Cibaca lime gel toothpaste; consumer health care sales affected by chloride controversy.
- Agricultural division launches APRON 35 WS seed dressing fungicide.
- Commissions saturated polyester resin unit in Goa.
- Reassesses anti-oxidants project due to rupee devaluation and import policy changes.
- Issues Rs 1000 lakhs 15.5% secured NCD on private placement, redeemable at 5% premium in three instalments after six years.
1992
- Commissions monocrotophos plant at Santa Monica Works.
- Suspends production at Bhandup plant due to losses.
- Plans phased implementation of anti-oxidants project at Goa.
- Plans launch of diazinon-based formulation.
1993
- Introduces Cibaca Gel toothpaste.
- Pharma division launches Nitroderm-TTS for angina patients.
- Agricultural division divided into Crop Protection and Animal Health.
- Enters JV agreement with Ciba-Geigy Switzerland and Chong Kun Dang Korea for Ciba CKD Biochem to manufacture Rifampicin at Mahad.
1994
- Introduces Protexin and ESB 3.
- Commissions Tinopal CBS-X plant with 1000 tpa capacity and chemical waste incinerator.
1995
- Introduces Combi-Pack 4D, Ebutol, Regestrone HRT, PZA suspension.
- Ciba CKD Biochem Ltd becomes subsidiary effective 29 March.
- Shareholders approve merger of Ciba-Geigy AG and Sandoz AG to form Novartis.
1996
- Launches pharma products: Lamisil, Leponex, Lioresal, Orfiz, Parlodel, Voltaflam.
- Proposes closure of Kandla export unit.
- Approvals received for demerger, share subdivision from Rs 100 to 10x Rs 10, and share exchange with Sandoz India Ltd.
- Share allotment executed for demerger into Ciba Geigy Speciality Chemicals and Novartis India.
1997
- Introduces Topik speciality herbicide for wheat; expands market presence.
- Forms JV Indo-Swiss Chemicals Ltd to market polyester and celluloid dyes.
- Trims labour force by 13%; offers voluntary retirement scheme.
- Merger of Sandoz India with Hindustan Ciba-Geigy progresses.
- Walden fund acquires equity stake in Ciba-CKD Biochem JV.
- Transfers combined development team to Novartis Enterprises Private Limited.
1998
- Novartis India regains Triaminic cough and cold preparation.
- Board approves transfer of 29.22 lakh equity shares (9.17%) from Ciba India Pvt Ltd to Novartis AG.
1999
- Novartis India acquires Clearine eyedrop brand from Optrex Ltd through CibaVision.
2000
- Plans to spin off agribusiness into Novartis Agribusiness India Pvt. Ltd.
- Shareholders offered one NAIPL equity share of Rs 5 for each Novartis India share.
- Novartis India joins Global Working Alliance on Tuberculosis drug development.
- Novartis launches Calcium Sandoz OTC in American Ice Cream and Orange flavours.
2001
- P1+ rating reaffirmed for Rs 50-crore CP programme.
- Novartis India and Ciba Speciality Chemicals sign LOI for sale of Goregaon properties to Kingston Properties.
2002
- Board changes: Dr R Thompson ceases as Director; R Sahani appointed Vice Chairman and Managing Director; Asha Mirchnandani joins as Executive Finance Director.
2003
- Anil Matai appointed CEO, Pharmaceuticals.
- Novartis unveils Myfortic enteric-coated immunosuppressant.
- Novartis changes import currency to US Dollar from Swiss Franc.
- Novartis completes transfer of third Goregaon land plot for Rs 171.07 million.
2004
- Charak Pharma allies with Novartis India for promotion of three animal healthcare products.
- Novartis Pharma AG establishes software development centre in Mumbai.
- Novartis establishes third plant in Mumbai.
- Syngene International enters contract research agreement with Novartis Institutes for Biomedical Research.
- Novartis launches Otrivin-O spray.
2005
- Novartis India approves sale of Rifampicin bulk drug business.
- Novartis files patent application for blood cancer drug.
2006
- Hikal's Jai Hiremath appointed Director on Novartis India Ltd board.
2007
- Dr. P Jager appointed Director and Chairman succeeding Dr. Schillinger.
2010
- European Commission approves Novartis meningitis vaccine Menveo.
- Novartis launches rural sales initiative Arogya Parivar to double reach in India.
2011
- Novartis India recommends dividend Rs 10 per equity share of Rs 5.
2012
- Novartis India recommends dividend Rs 10 per equity share of Rs 5.
2013
- Novartis India recommends dividend Rs 10 per equity share of Rs 5.
2014
- Novartis India recommends dividend Rs 10 per equity share of Rs 5.
2016
- Novartis featured as one of the 2016 Top 100 Global Innovators.
- Novartis ranks #2 in FORTUNE World's Most Admired Companies Pharmaceuticals Industry list.
- Novartis ranks third in 2016 Access to Medicine Index.
- Two Novartis products receive 2016 Prix Galien Foundation Awards.
- Novartis receives A- rating in 2016 CDP Climate Score.
2017
- Novartis on FORTUNE's list of the World's Most Admired Companies 2017.
2018
- Novartis ranks second in 2018 Access to Medicine Index.
2019
- Novartis recognized with Learning Strategy Innovation Award 2019.
- Novartis makes the 2019 Top Employer list from Science Magazine.
2020
- Novartis launches Biome India, a digital innovation hub in Hyderabad.
- Novartis receives bronze award for best People Development Program 2020.
2021
- Novartis recognized as Global Top Employer for 2021.
- Novartis ranks second in 2021 Access to Medicine Index.